治疗癌症相关血栓的直接口服抗凝剂。

Q4 Medicine

Ugeskrift for laeger Pub Date : 2024-10-14 DOI:10.61409/V04240299

Maja Hellfritzsch Poulsen, Thomas Kümler, Morten Kjøbek Lamberts, Christina Halgaard Ruhlmann, Erik Lerkevang Grove

{"title":"治疗癌症相关血栓的直接口服抗凝剂。","authors":"Maja Hellfritzsch Poulsen, Thomas Kümler, Morten Kjøbek Lamberts, Christina Halgaard Ruhlmann, Erik Lerkevang Grove","doi":"10.61409/V04240299","DOIUrl":null,"url":null,"abstract":"Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.","PeriodicalId":23428,"journal":{"name":"Ugeskrift for laeger","volume":"186 42","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Direct oral anticoagulants for the treatment of cancer-associated thrombosis.\",\"authors\":\"Maja Hellfritzsch Poulsen, Thomas Kümler, Morten Kjøbek Lamberts, Christina Halgaard Ruhlmann, Erik Lerkevang Grove\",\"doi\":\"10.61409/V04240299\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.\",\"PeriodicalId\":23428,\"journal\":{\"name\":\"Ugeskrift for laeger\",\"volume\":\"186 42\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-10-14\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ugeskrift for laeger\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.61409/V04240299\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ugeskrift for laeger","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.61409/V04240299","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

癌症相关血栓形成（CAT）仍然是癌症患者治疗过程中的一项挑战。本综述讨论了抗凝剂治疗癌症相关血栓的相关证据，尤其侧重于直接口服抗凝剂（DOAC）。阿哌沙班、利伐沙班和依度沙班已被证明是低分子量肝素的有吸引力的替代药物，而且与癌症内科治疗的相互作用并不构成重大挑战。大多数指南都认可使用 DOAC，我们将重点介绍为患者选择最佳抗凝剂时应考虑的要点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Direct oral anticoagulants for the treatment of cancer-associated thrombosis.

Cancer-associated thrombosis (CAT) remains a challenging aspect of managing patients with cancer. This review discusses evidence regarding anticoagulants in the treatment of CAT, with particular emphasis on direct oral anticoagulants (DOAC). Apixaban, rivaroxaban and edoxaban have proven attractive alternatives to low-molecular weight heparins, and interactions with medical cancer treatment does not pose a major challenge. The majority of guidelines have endorsed the use of DOAC, and we highlight points to consider when choosing the optimal anticoagulant for the individual patient.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Ugeskrift for laeger Medicine-Medicine (all)

CiteScore

0.20

自引率

0.00%

发文量

345

期刊介绍： The Ulster Medical Journal is an international general medical journal with contributions on all areas of medical and surgical specialties relevant to a general medical readership. It retains a focus on material relevant to the health of the Northern Ireland population. The Honorary Editor would welcome offers of papers for publication. Prospective authors are invited to read the notice to contributors.